A comparative study of transient characteristics of argon and argon-hydrogen pulse modulated induction thermal plasma

Solving a time-dependent two-dimensional local thermodynamic equilibrium (LTE) model simulation of Ar and Ar-H2 atmospheric pressure, a high-power RF-induction thermal plasma was performed. The effects of shimmer current level (SCL) in pulse-modulated mode and hydrogen concentrations on different flow fields were predicted. The radiation intensities of Ar I (751 nm) for different SCL were calculated from the temperature fields. For the same operating conditions as simulation, plasma was successfully generated in pulse-modulated mode and spectroscopic measurements were carried out to investigate the effects of SCL upon temporal plasma properties. Response times (rising, falling, on-delay, and off-delay time) of temporal radiation intensity were crosschecked for both experimental and simulated ones. The rising time increased gradually with the decrease of SCL, though the falling time remained almost unchanged with SCL. For example, for Ar plasma at 86 percent , 79 percent , 72 percent , 65 percent , 50 percent , and 40 percent SCL the rising times were 2.7, 3.0, 3.4, 3.4, 3.6, and 3.8 ms, respectively. And for Ar-H2 plasma (2.4 percent H2), at 87 percent , 77 percent , 72 percent , 63 percent , 55 percent , and 45 percent SCL, rising times were 2.5, 3.0, 3.0, 3.4, 3.7, 3.9, and 4.0 ms, respectively. Hydrogen inclusion slowed down the plasma response during the off-to-on pulsing transition at lower SCL and constricted the plasma axially. Finally, part of the simulated results was compared with experimental determinations and acceptable agreements were found. The discrepancies, in few cases, explicated mainly that the LTE assumption did not prevail in pulse-modulated plasma, especially around the on-pulse transitio

Responses of a long-coil pulse-modulated induction plasma

Radio-frequency inductively coupled plasma in a pulse modulated approach was generated by a MOSFET inverter supply of high electric efficiency. The plasma torch has an extremely long coil region of 153 mm, which is an attractive feature for advanced materials processing, especially for better and more efficient vaporizing of solids. The operating conditions were: argon flow of 80 or 90 L/m at atmospheric pressure; supply power of 30 kW; and pulse on-time of 10 ms at 67% duty factor. Spectroscopic measurements were carried out to determine the temporal plasma properties, including the effects of shimmer current level (SCL) upon the spectral intensities. Additionally a time-dependent two-dimensional numerical model was solved for the same operating conditions employed in the experiment to predict and compare the plasma properties. Pulsed plasma dissipation sustained for a minimum SCL of 43% for 80 L/m gas flow-rate, and at any level below 43%, the plasma disappeared. Temporal variation of argon line intensities at 751 and 763.5 nm is similar, though the upper level intensity of the former one was significantly stronger than the latter. Intensified change of intensity is found at lower SCL because of higher change in the coil current and, in turn, in the plasma power. The predicted intensity of the 751-nm argon line showed similar behavior to the experimental intensity though the response around the instant of on-pulsation is somewhat slowe

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

The aim of this 12-month, observational study was to compare the effects of switching daily teriparatide (TPTD) to oral bisphosphonates (BP) therapy or denosumab (DMAb) therapy in patients with primary osteoporosis. Patients [n = 78; 71 postmenopausal women and seven men; mean age 76.3 (64–94) years; mean duration of prior daily TPTD therapy 20.1 (6–24) months] were allocated to either the (1) “switch-to-BP” group [n = 36; weekly alendronate 35 mg (n = 19), weekly risedronate 17.5 mg (n = 12), monthly minodronate 50 mg (n = 5)]; or (2) “switch-to-DMAb” group (n = 42; 60 mg sc every 6 months) based on each physicians’ decision. Changes in bone mineral density (BMD) and serum bone turnover markers were monitored every 6 months. No significant difference was observed in baseline clinical characteristics between the groups. After 12 months, the increase in BMD was significantly greater in the switch-to-DMAb group compared to the switch-to-BP group: lumbar spine (6.2 vs. 2.6 %; P < 0.01), total hip (4.2 vs. 1.1 %; P < 0.05), and femoral neck (3.5 vs. 1.4 %; P < 0.05). In addition, the patients in the switch-to-DMAb group showed a significant decrease compared to those in the switch-to-BP group in TRACP-5b (−55.8 vs. −32.8 %; P < 0.01) and ucOC (−85.5 vs. −65.0 %; P < 0.001), while no significant difference was observed in PINP (−67.5 vs. −62.1 %). Switching daily TPTD to DMAb significantly increased BMD and decreased bone resorption marker compared to switching to oral BP at 12 months, and thus may provide an effective sequential treatment option after daily TPTD treatment.This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00774-015-0731-xEbina K., Hashimoto J., Kashii M., et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. Journal of Bone and Mineral Metabolism 35, 91 (2017); https://doi.org/10.1007/s00774-015-0731-x

Bifunctionality of Rh3+ Modifier on TiO2 and Working Mechanism of Rh3+/TiO2 Photocatalyst under Irradiation of Visible Light

A rhodium(III) ion (Rh3+)-modified TiO2 (Rh3+/TiO2) photocatalyst, prepared by a simple adsorption method and exhibiting high levels of photocatalytic activity in degradation of organic compounds, was investigated by using X-ray absorption fine structure (XAFS) measurements, (photo)electrochemical measurements, double-beam photoacoustic (DB-PA) spectroscopic measurements, and photoluminescence measurements. Based on the results, the features of the Rh3+ modifier and the working mechanism of the Rh3+/TiO2 photocatalyst are discussed. XAFS measurements revealed that the Rh3+ species were highly dispersed and almost atomically isolated on TiO2. The (photo)electrochemical measurements, DB-PA spectroscopic measurements, and photoluminescence showed a unique bifunction of the Rh3+ modifier as a promoter for O2 reductions and an electron injector to the conduction band of TiO2 for response to visible light. The reasons for the Rh3+/TiO2 photocatalyst exhibiting higher levels of photocatalytic activity than those of TiO2 photocatalysts modified with other metal ions are also discussed on the basis of obtained results

Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis

The aim of this 12-month, retrospective study was to compare the effects of denosumab (DMAb; 60 mg subcutaneously every 6 months) plus native vitamin D (VD) (cholecalciferol) combination therapy with DMAb plus active VD analog (alfacalcidol) combination therapy in patients with postmenopausal osteoporosis. Patients [N = 127; mean age 75.6 years (range 58–93 years); 28 treatment-naïve patients, 59 patients treated with oral bisphosphonate therapy, 40 patients treated with teriparatide daily] were allocated to either (1) the DMAb plus native VD group (n = 60; cholecalciferol, 10 μg, plus calcium, 610 mg/day; 13 treatment-naïve patients, 28 patients treated with oral bisphosphonate therapy, and 19 patients treated with teriparatide daily) or (2) the DMAb plus active VD group [n = 67; alfacalcidol, 0.8 ± 0.0 μg, plus calcium, 99.2 ± 8.5 mg/day; 15 treatment-naïve patients, 31 patients treated with oral bisphosphonate therapy, and 21 patients treated with teriparatide daily) on the basis of each physician’s decision. Changes in bone mineral density (BMD), serum bone turnover marker levels, and fracture incidence were monitored every 6 months. There were no significant differences in baseline age, BMD, bone turnover marker levels, and prior treatments between the two groups. After 12 months, compared with the DMAb plus native VD group, the DMAb plus active VD group showed similar increases in the BMD of the lumbar spine (6.4% vs 6.5%) and total hip (3.3% vs 3.4%), but significantly greater increases in the BMD of the femoral neck (1.0% vs 4.9%, P < 0.001) and the distal part of the forearm (third of radius) (−0.8% vs 3.9%, P < 0.01). These tendencies were similar regardless of the differences in the prior treatments. The rates of decrease of bone turnover marker levels were similar for tartrate-resistant acid phosphatase isoform 5b (−49.0% vs −49.0%), procollagen type I N-terminal propeptide (−45.9% vs −49.3%), and undercarboxylated osteocalcin (−56.0 vs −66.5%), whereas serum intact parathyroid hormone levels were significantly lower in the DMAb plus active VD group (47.6 pg/mL vs 30.4 pg/mL, P < 0.001). The rate of hypocalcemia was 1.7% in the DMAb plus native VD group and 1.5% in the DMAb plus active VD group, and the rate of clinical fracture incidence was 8.3% in the DMAb plus native VD group and 4.5% in the DMAb plus active VD group, with no significant difference between the groups. DMAb with active VD combination therapy may be a more effective treatment option than DMAb with native VD combination therapy in terms of increasing BMD of the femoral neck and distal part of the forearm and also maintaining serum intact parathyroid hormone at lower levels.This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00774-016-0792-5Ebina K., Kashii M., Hirao M., et al. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism 35, 571 (2017); https://doi.org/10.1007/s00774-016-0792-5

Precision measurements of positronium decay rate and energy level

Positronium is an ideal system for the research of the bound state QED. New precise measurement of orthopositronium decay rate has been performed with an accuracy of 150 ppm, and the result combined with the last three is 7.0401 +- 0.0007 mu s^-1. It is the first result to validate the 2nd order correction. The Hyper Fine Splitting of positronium is sensitive to the higher order corrections of the QED prediction and also to the new physics beyond Standard Model via the quantum oscillation into virtual photon. The discrepancy of 3.5 sigma is found recently between the measured values and the QED prediction (O(alpha^3)). It might be due to the contribution of the new physics or the systematic problems in the previous measurements: (non-thermalized Ps and non-uniformity of the magnetic field). We propose new methods to measure HFS precisely without the these uncertainties.Comment: This note contributes to pbar0